179 related articles for article (PubMed ID: 33361107)
1. Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1.
Ryan K; Bolaňos B; Smith M; Palde PB; Cuenca PD; VanArsdale TL; Niessen S; Zhang L; Behenna D; Ornelas MA; Tran KT; Kaiser S; Lum L; Stewart A; Gajiwala KS
J Biol Chem; 2021; 296():100251. PubMed ID: 33361107
[TBL] [Abstract][Full Text] [Related]
2. E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.
McGonigle S; Chen Z; Wu J; Chang P; Kolber-Simonds D; Ackermann K; Twine NC; Shie JL; Miu JT; Huang KC; Moniz GA; Nomoto K
Oncotarget; 2015 Dec; 6(38):41307-23. PubMed ID: 26513298
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
[TBL] [Abstract][Full Text] [Related]
4. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
Thorsell AG; Ekblad T; Karlberg T; Löw M; Pinto AF; Trésaugues L; Moche M; Cohen MS; Schüler H
J Med Chem; 2017 Feb; 60(4):1262-1271. PubMed ID: 28001384
[TBL] [Abstract][Full Text] [Related]
5. Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
Boussios S; Abson C; Moschetta M; Rassy E; Karathanasi A; Bhat T; Ghumman F; Sheriff M; Pavlidis N
Drugs R D; 2020 Jun; 20(2):55-73. PubMed ID: 32215876
[TBL] [Abstract][Full Text] [Related]
6. Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.
Chornenkyy Y; Agnihotri S; Yu M; Buczkowicz P; Rakopoulos P; Golbourn B; Garzia L; Siddaway R; Leung S; Rutka JT; Taylor MD; Dirks PB; Hawkins C
Mol Cancer Ther; 2015 Nov; 14(11):2560-8. PubMed ID: 26351319
[TBL] [Abstract][Full Text] [Related]
7. PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation.
Jonuscheit S; Jost T; Gajdošová F; Wrobel M; Hecht M; Fietkau R; Distel L
Genes (Basel); 2021 May; 12(6):. PubMed ID: 34073147
[TBL] [Abstract][Full Text] [Related]
8. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
Jain PG; Patel BD
Eur J Med Chem; 2019 Mar; 165():198-215. PubMed ID: 30684797
[TBL] [Abstract][Full Text] [Related]
9. Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.
Srinivasan G; Sidhu GS; Williamson EA; Jaiswal AS; Najmunnisa N; Wilcoxen K; Jones D; George TJ; Hromas R
Cancer Chemother Pharmacol; 2017 Oct; 80(4):861-867. PubMed ID: 28756516
[TBL] [Abstract][Full Text] [Related]
10. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
11. A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer.
Postel-Vinay S; Bajrami I; Friboulet L; Elliott R; Fontebasso Y; Dorvault N; Olaussen KA; André F; Soria JC; Lord CJ; Ashworth A
Oncogene; 2013 Nov; 32(47):5377-87. PubMed ID: 23934192
[TBL] [Abstract][Full Text] [Related]
12. Rational design, synthesis and biological evaluation of dual PARP-1/2 and TNKS1/2 inhibitors for cancer therapy.
Xu Y; Wu H; Huang L; Zhai B; Li X; Xu S; Wu X; Zhu Q; Xu Q
Eur J Med Chem; 2022 Jul; 237():114417. PubMed ID: 35504210
[TBL] [Abstract][Full Text] [Related]
13. Histone Parylation factor 1 contributes to the inhibition of PARP1 by cancer drugs.
Rudolph J; Roberts G; Luger K
Nat Commun; 2021 Feb; 12(1):736. PubMed ID: 33531508
[TBL] [Abstract][Full Text] [Related]
14. Clinical PARP inhibitors do not abrogate PARP1 exchange at DNA damage sites in vivo.
Shao Z; Lee BJ; Rouleau-Turcotte É; Langelier MF; Lin X; Estes VM; Pascal JM; Zha S
Nucleic Acids Res; 2020 Sep; 48(17):9694-9709. PubMed ID: 32890402
[TBL] [Abstract][Full Text] [Related]
15. PARP inhibitors trap PARP2 and alter the mode of recruitment of PARP2 at DNA damage sites.
Lin X; Jiang W; Rudolph J; Lee BJ; Luger K; Zha S
Nucleic Acids Res; 2022 Apr; 50(7):3958-3973. PubMed ID: 35349716
[TBL] [Abstract][Full Text] [Related]
16. Investigation of the Complexes Formed between PARP1 Inhibitors and PARP1 G-Quadruplex at the Gene Promoter Region.
Dallavalle S; Princiotto S; Mattio LM; Artali R; Musso L; Aviñó A; Eritja R; Pisano C; Gargallo R; Mazzini S
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445442
[TBL] [Abstract][Full Text] [Related]
17. PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib.
Ding X; Zhu Z; Lapek J; McMillan EA; Zhang A; Chung CY; Dubbury S; Lapira J; Firdaus S; Kang X; Gao J; Oyer J; Chionis J; Rollins RA; Li L; Niessen S; Bagrodia S; Zhang L; VanArsdale T
Sci Rep; 2022 Jul; 12(1):12501. PubMed ID: 35864202
[TBL] [Abstract][Full Text] [Related]
18. A decade of clinical development of PARP inhibitors in perspective.
Mateo J; Lord CJ; Serra V; Tutt A; Balmaña J; Castroviejo-Bermejo M; Cruz C; Oaknin A; Kaye SB; de Bono JS
Ann Oncol; 2019 Sep; 30(9):1437-1447. PubMed ID: 31218365
[TBL] [Abstract][Full Text] [Related]
19. XRCC1 counteracts poly(ADP ribose)polymerase (PARP) poisons, olaparib and talazoparib, and a clinical alkylating agent, temozolomide, by promoting the removal of trapped PARP1 from broken DNA.
Hirota K; Ooka M; Shimizu N; Yamada K; Tsuda M; Ibrahim MA; Yamada S; Sasanuma H; Masutani M; Takeda S
Genes Cells; 2022 May; 27(5):331-344. PubMed ID: 35194903
[TBL] [Abstract][Full Text] [Related]
20. The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors.
Palve V; Knezevic CE; Bejan DS; Luo Y; Li X; Novakova S; Welsh EA; Fang B; Kinose F; Haura EB; Monteiro AN; Koomen JM; Cohen MS; Lawrence HR; Rix U
Cell Chem Biol; 2022 Feb; 29(2):202-214.e7. PubMed ID: 34329582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]